Plasmodium vivax malaria is difficult to manage because even after taking medicine that kills
the infection in the blood, it can continue to hide quietly in the liver, later re-emerging
into the blood and causing another episode of malaria illness (relapse). This clinical trial
aims to enroll patient with P. vivax infections and try to detect signals in blood, urine
and/or saliva coming from the silent liver stages to help identify who could benefit from
treatment with primaquine. It also will explore if certain factors of patients negatively
impact primaquine efficacy.
Phase:
N/A
Details
Lead Sponsor:
Armed Forces Research Institute of Medical Sciences, Thailand